L'ipertensione arteriosa polmonare. Parte II: Terapia medica e chirurgica

Translated title of the contribution: Pulmonary arterial hypertension. Part II: Medical and surgical treatment

Alessandra Manes, Alessandro Marinelli, Massimiliano Palazzini, Luca Negro, Enri Leci, Simona Gambetti, Cristina Bachetti, Elena Beciani, Elisa Conficoni, Angelo Branzi, Nazzareno Galiè

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Treatment of pulmonary arterial hypertension (group 1 of clinical classification) has been recently characterized by important progresses, particularly in pharmacological therapy. Only until few years ago, patients with pulmonary arterial hypertension were treated with non-specific drugs, such as diuretics and digoxin for right heart failure and calcium-channel blockers in the minority of cases, responders to the acute vasoreactivity test. In addition, use of oral anticoagulant treatment was supported by uncontrolled studies. In the last 15 years (in particular in the last 8 years) different randomized controlled trials assessing the functional, clinical and hemodynamic efficacy of three classes of targeted drugs (prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors) with pulmonary vascular dilating and antiproliferative effects have been performed. This information has allowed the proposal of an evidence-based treatment algorithm. Treatment starts with general measures (physical activity, fertility control, respiratory tract infection, etc.) and supportive therapy (anticoagulant therapy, diuretics, oxygen, digoxin). Patients who respond to the acute vasoreactivity test (10% of idiopathic form) are treated with high doses of calcium-channel blockers, non-responders with targeted therapies either on monotherapy or combination. Usually an oral active drug is initiated and a second compound of a different class is combined in case of non-satisfactory response to the first treatment. Combination therapy should be performed only in specialized centers with large experience on use of targeted therapies and their relevant side effects. In case of failure of medical therapy, possible options are balloon atrial septostomy and/or listing for lung or heart-lung transplantation. As available treatments do not constitute a cure for pulmonary arterial hypertension, further progresses are expected in the near future.

Original languageItalian
Pages (from-to)366-381
Number of pages16
JournalGiornale Italiano di Cardiologia
Volume10
Issue number6
Publication statusPublished - 2009

Fingerprint

Pulmonary Hypertension
Therapeutics
Digoxin
Calcium Channel Blockers
Diuretics
Anticoagulants
Pharmaceutical Preparations
Heart-Lung Transplantation
Phosphodiesterase 5 Inhibitors
Lung
Contraception
Respiratory Tract Infections
Prostaglandins
Blood Vessels
Randomized Controlled Trials
Heart Failure
Hemodynamics
Pharmacology
Exercise
Oxygen

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Manes, A., Marinelli, A., Palazzini, M., Negro, L., Leci, E., Gambetti, S., ... Galiè, N. (2009). L'ipertensione arteriosa polmonare. Parte II: Terapia medica e chirurgica. Giornale Italiano di Cardiologia, 10(6), 366-381.

L'ipertensione arteriosa polmonare. Parte II : Terapia medica e chirurgica. / Manes, Alessandra; Marinelli, Alessandro; Palazzini, Massimiliano; Negro, Luca; Leci, Enri; Gambetti, Simona; Bachetti, Cristina; Beciani, Elena; Conficoni, Elisa; Branzi, Angelo; Galiè, Nazzareno.

In: Giornale Italiano di Cardiologia, Vol. 10, No. 6, 2009, p. 366-381.

Research output: Contribution to journalArticle

Manes, A, Marinelli, A, Palazzini, M, Negro, L, Leci, E, Gambetti, S, Bachetti, C, Beciani, E, Conficoni, E, Branzi, A & Galiè, N 2009, 'L'ipertensione arteriosa polmonare. Parte II: Terapia medica e chirurgica', Giornale Italiano di Cardiologia, vol. 10, no. 6, pp. 366-381.
Manes A, Marinelli A, Palazzini M, Negro L, Leci E, Gambetti S et al. L'ipertensione arteriosa polmonare. Parte II: Terapia medica e chirurgica. Giornale Italiano di Cardiologia. 2009;10(6):366-381.
Manes, Alessandra ; Marinelli, Alessandro ; Palazzini, Massimiliano ; Negro, Luca ; Leci, Enri ; Gambetti, Simona ; Bachetti, Cristina ; Beciani, Elena ; Conficoni, Elisa ; Branzi, Angelo ; Galiè, Nazzareno. / L'ipertensione arteriosa polmonare. Parte II : Terapia medica e chirurgica. In: Giornale Italiano di Cardiologia. 2009 ; Vol. 10, No. 6. pp. 366-381.
@article{2222325b649c44529498b2e6311b2e50,
title = "L'ipertensione arteriosa polmonare. Parte II: Terapia medica e chirurgica",
abstract = "Treatment of pulmonary arterial hypertension (group 1 of clinical classification) has been recently characterized by important progresses, particularly in pharmacological therapy. Only until few years ago, patients with pulmonary arterial hypertension were treated with non-specific drugs, such as diuretics and digoxin for right heart failure and calcium-channel blockers in the minority of cases, responders to the acute vasoreactivity test. In addition, use of oral anticoagulant treatment was supported by uncontrolled studies. In the last 15 years (in particular in the last 8 years) different randomized controlled trials assessing the functional, clinical and hemodynamic efficacy of three classes of targeted drugs (prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors) with pulmonary vascular dilating and antiproliferative effects have been performed. This information has allowed the proposal of an evidence-based treatment algorithm. Treatment starts with general measures (physical activity, fertility control, respiratory tract infection, etc.) and supportive therapy (anticoagulant therapy, diuretics, oxygen, digoxin). Patients who respond to the acute vasoreactivity test (10{\%} of idiopathic form) are treated with high doses of calcium-channel blockers, non-responders with targeted therapies either on monotherapy or combination. Usually an oral active drug is initiated and a second compound of a different class is combined in case of non-satisfactory response to the first treatment. Combination therapy should be performed only in specialized centers with large experience on use of targeted therapies and their relevant side effects. In case of failure of medical therapy, possible options are balloon atrial septostomy and/or listing for lung or heart-lung transplantation. As available treatments do not constitute a cure for pulmonary arterial hypertension, further progresses are expected in the near future.",
keywords = "Endothelin receptor antagonists, Medical surgery, Phosphodiesterase inhibitors, Prostanoids, Pulmonary hypertension, Surgery",
author = "Alessandra Manes and Alessandro Marinelli and Massimiliano Palazzini and Luca Negro and Enri Leci and Simona Gambetti and Cristina Bachetti and Elena Beciani and Elisa Conficoni and Angelo Branzi and Nazzareno Gali{\`e}",
year = "2009",
language = "Italian",
volume = "10",
pages = "366--381",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "6",

}

TY - JOUR

T1 - L'ipertensione arteriosa polmonare. Parte II

T2 - Terapia medica e chirurgica

AU - Manes, Alessandra

AU - Marinelli, Alessandro

AU - Palazzini, Massimiliano

AU - Negro, Luca

AU - Leci, Enri

AU - Gambetti, Simona

AU - Bachetti, Cristina

AU - Beciani, Elena

AU - Conficoni, Elisa

AU - Branzi, Angelo

AU - Galiè, Nazzareno

PY - 2009

Y1 - 2009

N2 - Treatment of pulmonary arterial hypertension (group 1 of clinical classification) has been recently characterized by important progresses, particularly in pharmacological therapy. Only until few years ago, patients with pulmonary arterial hypertension were treated with non-specific drugs, such as diuretics and digoxin for right heart failure and calcium-channel blockers in the minority of cases, responders to the acute vasoreactivity test. In addition, use of oral anticoagulant treatment was supported by uncontrolled studies. In the last 15 years (in particular in the last 8 years) different randomized controlled trials assessing the functional, clinical and hemodynamic efficacy of three classes of targeted drugs (prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors) with pulmonary vascular dilating and antiproliferative effects have been performed. This information has allowed the proposal of an evidence-based treatment algorithm. Treatment starts with general measures (physical activity, fertility control, respiratory tract infection, etc.) and supportive therapy (anticoagulant therapy, diuretics, oxygen, digoxin). Patients who respond to the acute vasoreactivity test (10% of idiopathic form) are treated with high doses of calcium-channel blockers, non-responders with targeted therapies either on monotherapy or combination. Usually an oral active drug is initiated and a second compound of a different class is combined in case of non-satisfactory response to the first treatment. Combination therapy should be performed only in specialized centers with large experience on use of targeted therapies and their relevant side effects. In case of failure of medical therapy, possible options are balloon atrial septostomy and/or listing for lung or heart-lung transplantation. As available treatments do not constitute a cure for pulmonary arterial hypertension, further progresses are expected in the near future.

AB - Treatment of pulmonary arterial hypertension (group 1 of clinical classification) has been recently characterized by important progresses, particularly in pharmacological therapy. Only until few years ago, patients with pulmonary arterial hypertension were treated with non-specific drugs, such as diuretics and digoxin for right heart failure and calcium-channel blockers in the minority of cases, responders to the acute vasoreactivity test. In addition, use of oral anticoagulant treatment was supported by uncontrolled studies. In the last 15 years (in particular in the last 8 years) different randomized controlled trials assessing the functional, clinical and hemodynamic efficacy of three classes of targeted drugs (prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors) with pulmonary vascular dilating and antiproliferative effects have been performed. This information has allowed the proposal of an evidence-based treatment algorithm. Treatment starts with general measures (physical activity, fertility control, respiratory tract infection, etc.) and supportive therapy (anticoagulant therapy, diuretics, oxygen, digoxin). Patients who respond to the acute vasoreactivity test (10% of idiopathic form) are treated with high doses of calcium-channel blockers, non-responders with targeted therapies either on monotherapy or combination. Usually an oral active drug is initiated and a second compound of a different class is combined in case of non-satisfactory response to the first treatment. Combination therapy should be performed only in specialized centers with large experience on use of targeted therapies and their relevant side effects. In case of failure of medical therapy, possible options are balloon atrial septostomy and/or listing for lung or heart-lung transplantation. As available treatments do not constitute a cure for pulmonary arterial hypertension, further progresses are expected in the near future.

KW - Endothelin receptor antagonists

KW - Medical surgery

KW - Phosphodiesterase inhibitors

KW - Prostanoids

KW - Pulmonary hypertension

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=67649218372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649218372&partnerID=8YFLogxK

M3 - Articolo

C2 - 19603608

AN - SCOPUS:67649218372

VL - 10

SP - 366

EP - 381

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 6

ER -